Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Christian Ruff, MD
Advertisement
Articles by Christian Ruff, MD
Christian T. Ruff, MD, MPH, of Brigham and Women's Hospital, discusses new data comparing abelacimab with rivaroxaban in patients with atrial fibrillation presented at the American College of Cardiology 2025 Annual Scientific Session.
Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.
Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.
Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).
Advertisement
Latest Updated Articles
Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 TrialPublished: January 22nd 2025 | Updated:
Abelacimab Shows Unprecedented Bleeding Risk Reduction in Patients With Atrial FibrillationPublished: March 30th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology
4
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
5
